γ-Camera 18F-FDG PET in diagnosis and staging of patients presenting with suspected lung cancer and comparison with dedicated PET

Journal of Nuclear Medicine

Volumn 45, Issue 8, 2004, Pages 1351-1357

  Oturai, Peter S ^a,b   Mortensen, Jann ^c   Enevoldsen, Henriette ^a   Eigtved, Annika ^c   Backer, Vibeke ^a   Olesen, Knud P ^a   Nielsen, Henrik W ^a   Hansen, Hanne ^a   Stentoft, Poul ^c   Friberg, Lars ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c University of Copenhagen   (Denmark)

Author keywords

camera coincidence; 18F FDG; Lung cancer; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CARCINOID; COLON CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCINTILLATION CAMERA; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; THORAX RADIOGRAPHY; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EQUIPMENT; INSTRUMENTATION; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; SCINTISCANNING; SINGLE BLIND PROCEDURE; VALIDATION STUDY;

EQUIPMENT FAILURE ANALYSIS; FEMALE; FLUORODEOXYGLUCOSE F18; GAMMA CAMERAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 4544303326     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med. 2002;53:89-112.
2. Shon IH, O'Doherty MJ, Maisey MN. Positron emission tomography in lung cancer. Semin Nucl Med. 2002;32:240-271.
3. Saunders CA, Dussek JE, O'Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg. 1999;67:790-797.
4. Fischer BM, Mortensen J, Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol. 2001;2:659-666.
5. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596-1604.
6. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359:1388-1393.
7. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med. 1996;37:1428-1436.
8. Gambhir SS, Shepherd JE, Shah BD, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol. 1998;16:2113-2125.
9. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. Eur J Nucl Med. 2000;27:1441-1456.
10. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med. 2000;27:1598-1609.
11. 18F-FDG detection with a dual-head coincidence camera: a review. Eur J Nucl Med. 2001;28:763-778.
12. Patton JA. Instrumentation for coincidence imaging with multihead scintillation cameras. Semin Nucl Med. 2000;30:239-254.
13. Delbeke D, Sandler MP. The role of hybrid cameras in oncology. Semin Nucl Med. 2000;30:268-280.
14. Kim S, Park CH, Han M, Hwang S, Lee C, Pai M. The clinical usefulness of F-18 FDG coincidence PET without attenuation correction and without whole-body scanning mode in pulmonary lesions comparison with CT, MRI, and clinical findings. Clin Nucl Med. 1999;24:945-949.
15. 18F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras. J Nucl Med. 1999;40:574-578.
16. Bousson V, Moretti JL, Weinmann P, et al. Assessment of malignancy in pulmonary lesions: FDG dual-head coincidence gamma camera imaging in association with serum tumor marker measurement. J Nucl Med. 2000;41:1801-1807.
17. Roman MR, Rossleigh MA, Angelides S, Walker BM, Dixon J. Staging and managing lung tumors using F-18 FDG coincidence detection. Clin Nucl Med. 2001;26:383-388.
18. Schmid RA, Hautmann H, Poellinger B, et al. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET). Nucl Med Commun. 2003;24:37-45.
19. 18F-FDG for detection and nodal staging of non-small cell lung cancer: accuracy as determined by 2 independent observers. J Nucl Med. 2003;44:336-340.
20. Shreve PD, Steventon RS, Deters EC, Kison PV, Gross MD, Wahl RL. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology. 1998;207:431-437.
21. Weber WA, Neverve J, Sklarek J, et al. Imaging of lung cancer with fluorine-18 fluorodeoxyglucose: comparison of a dual-head gamma camera in coincidence mode with a full-ring positron emission tomography system. Eur J Nucl Med. 1999;26:388-395.
22. Tatsumi M, Yutani K, Watanabe Y, et al. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET. J Nucl Med. 1999;40:566-573.
23. Zhang H, Tian M, Oriuchi N, Higuchi T, Tanada S, Endo K. Oncological diagnosis using positron coincidence gamma camera with fluorodeoxyglucose in comparison with dedicated PET. Br J Radiol. 2002;75:409-416.
24. Zhang H, Inoue T, Tian M, et al. A basic study on lesion detectability for hot spot imaging of positron emitters with dedicated PET and positron coincidence gamma camera. Ann Nucl Med. 2001;15:301-306.
25. Dansk Lunge Cancer Gruppe. Referenceprogram 2001: Lungecancer- Undersøgelse og behandling. Århus, Denmark: Dansk Lunge Cancer Gruppe; 2001.
26. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE. Performance characteristics of a whole-body PET scanner. J Nucl Med. 1994;35:1398-1406.
27. Lababede O, Meziane MA, Rice TW. TNM staging of lung cancer: a quick reference chart. Chest. 1999;115:233-235.
28. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001;285:914-924.
29. Kubota K, Itoh M, Ozaki K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28:696-703.